Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081041 | SCV000112948 | uncertain significance | not provided | 2015-04-08 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001815180 | SCV000192851 | benign | not specified | 2021-06-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002311605 | SCV000846956 | likely benign | Inborn genetic diseases | 2016-04-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001085008 | SCV001013133 | likely benign | Rubinstein-Taybi syndrome | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000081041 | SCV001867847 | benign | not provided | 2020-10-21 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000081041 | SCV004140980 | likely benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | CREBBP: BP4, BP7, BS1 |
Diagnostic Laboratory, |
RCV000081041 | SCV001742065 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000081041 | SCV001972025 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003974971 | SCV004797820 | likely benign | CREBBP-related disorder | 2021-09-09 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |